GlassScriptPhysician profile
Charles A Ramkishun
NPI 1467849067
$559.09
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $36.66 · 2021: $204 · 2022: $155.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $158.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.07 | 2021 | |
| Mallinckrodt Hospital Products INC. | $100.00 | 2022 | |
| Melinta Therapeutics, LLC | $29.92 | 2021 | |
| Shionogi INC | $24.67 | 2022 | |
| Mylan Specialty L.P. | $23.69 | 2021 | |
| Coaptech, INC. | $22.22 | 2020 | |
| Insmed, INC. | $21.53 | 2021 | |
| Glaxosmithkline, LLC. | $19.69 | 2019 | |
| Chiesi USA, INC. | $15.64 | 2022 | |
| Merck Sharp & Dohme LLC | $14.76 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.44 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ramkishun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.